FDA grants fast review for Bayer/Merck & Co's heart failure ...

The FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being developed for chronic heart failure with reduced ejection fraction, followi

FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

AZ and Novoheart collaborate on 'heart in a jar', to develop...

Stem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will be used to help develop new heart failure drugs.

Merck/Bayer set to challenge Novartis in heart failure after...

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.<

Janssen taps wearable tech in Invokana heart failure trial

Boehringer, Lilly start acute heart failure trial with Jardi...